A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase

Mitchell, Lesley

doi:10.1002/cncr.11042

Cited by 250 publications

(226 citation statements)

References 42 publications

Supporting

Mentioning

206

Contrasting

Unclassified

Order By: Relevance

“…CVL-VT were reported being associated with left body side, subclavian vein placement and percutaneous technique insertion in children with ALL. [1][2][3] In the present study, the CVL location placement, as body side CVL insertion, vascular site and technique were not risk factors for development of VT (Table 2). This might be owing to the different distribution of catheter access, the great majority of our patients having CVL inserted via jugular vein and cut-down technique.…”

Section: Figurementioning

confidence: 74%

“…[1][2][3][4][5][6][7] We found no association between VT and characteristics of patients at diagnosis (Table 1). CVL-VT were reported being associated with left body side, subclavian vein placement and percutaneous technique insertion in children with ALL.…”

Section: Figurementioning

confidence: 97%

“…Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy, and a recent report from the European working group on myelodysplastic syndrome in Childhood (EWOG-MDS) indicates an event-free survival (EFS) of 52% at 5 years after HSCT. 1 Relapse remains the major cause of treatment failure, affecting about one-third of the patients following transplantation. 1 The optimal treatment strategy for patients who relapse after HSCT remains unknown.…”

Section: Figurementioning

confidence: 99%

“…1 Relapse remains the major cause of treatment failure, affecting about one-third of the patients following transplantation. 1 The optimal treatment strategy for patients who relapse after HSCT remains unknown. Withdrawal of immunosuppressive therapy is usually the first measure, which by itself can control the disease in a small number of patients, but the outcome of children given donor leukocyte infusion (DLI) for JMML recurrence is generally poor.…”

Section: Figurementioning

confidence: 99%

“…[1][2][3] Data on occurrence, risk factors and outcome of CVL-VT, as well as the gold-standard imaging test, are either limited or controversial. [1][2][3][4] A recent meta-analysis on thrombotic events in childhood ALL could not thoroughly evaluated the role of CVL as the proportion of patients bearing a CVL was reported by few prospective studies. 4 Recognizing the risk factors of CVL-related complications is important for assessing the benefit/risk ratio of these devices.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Risk factors of central venous lines-related thrombosis in children with acute lymphoblastic leukemia during induction therapy: a prospective study

et al. 2007

View full text Add to dashboard Cite

Section: Figurementioning

confidence: 74%

Section: Figurementioning

confidence: 97%

Section: Figurementioning

confidence: 99%

Section: Figurementioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Risk factors of central venous lines-related thrombosis in children with acute lymphoblastic leukemia during induction therapy: a prospective study

et al. 2007

View full text Add to dashboard Cite

Antithrombin III for critically ill patients

Afshari¹,

Wetterselv²,

Møller³

2008

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Antithrombin III for critically ill patients

Allingstrup

Wetterslev

Ravn

et al. 2016

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Our primary outcome measure was mortality. Two authors each independently abstracted data and resolved any disagreements by discussion. We presented pooled estimates of the intervention effects on dichotomous outcomes as risk ratios (RR) with 95% confidence intervals (CI). We performed subgroup analyses to assess risk of bias, the effect of AT III in different populations (sepsis, trauma, obstetrics, and paediatrics), and the effect of AT III in patients with or without the use of concomitant heparin. We assessed the adequacy of the available number of participants and performed trial sequential analysis (TSA) to establish the implications for further research. Main resultsWe included 30 RCTs with a total of 3933 participants (3882 in the primary outcome analyses).Combining all trials, regardless of bias, showed no statistically significant effect of AT III on mortality with a RR of 0.95 (95% CI 0.88 to 1.03), I² statistic = 0%, fixed-effect model, 29 trials, 3882 participants, moderate quality of evidence). For trials with low risk of bias the RR was 0.96 (95% Cl 0.88 to 1.04, I² statistic = 0%, fixed-effect model, 9 trials, 2915 participants) and for high risk of bias RR 0.94 (95% Cl 0.77 to 1.14, I² statistic = 0%, fixed-effect model, 20 trials, 967 participants).For participants with severe sepsis and DIC the RR for mortality was non-significant, 0.95 (95% Cl 0.88 to 1.03, I² statistic = 0%, fixed-effect model, 12 trials, 2858 participants, moderate quality of evidence).We conducted 14 subgroup and sensitivity analyses with respect to the different domains of risk of bias, but detected no statistically significant benefit in any subgroup analyses.Our secondary objective was to assess the benefits and harms of AT III. For complications specific to the trial intervention the RR was 1.26 (95% Cl 0.83 to 1.92, I² statistic = 0%, random-effect model, 3 trials, 2454 participants, very low quality of evidence). For complications not specific to the trial intervention, the RR was 0.71 (95% Cl 0.08 to 6.11, I² statistic = 28%, random-effects model, 2 trials, 65 participants, very low quality of evidence). For complications other than bleeding, the RR was 0.72 ( 95% Cl 0.42 to 1.25, I² statistic = 0%, fixed-effect model, 3 trials, 187 participants, very low quality of evidence). Eleven trials investigated bleeding events and we found a statistically significant increase, RR 1.58 (95% CI 1.35 to 1.84, I² statistic = 0%, fixed-effect model, 11 trials, 3019 participants, moderate quality of evidence) in the AT III group. The amount of red blood cells administered had a mean difference (MD) of 138.49 (95% Cl -391.35 to 668.34, I² statistic = 84%, random-effect model, 4 trials, 137 participants, very low quality of evidence). The effect of AT III in patients with multiple organ failure (MOF) was a MD of -1.24 (95% Cl -2.18 to -0.29, I² statistic = 48%, random-effects model, 3 trials, 156 participants, very low quality of evidence) and for patients with an Acute Physiology and Chronic Health Evaluation score (APACHE) at II a...

show abstract

A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L‐asparaginase

Cited by 250 publications

References 42 publications

Risk factors of central venous lines-related thrombosis in children with acute lymphoblastic leukemia during induction therapy: a prospective study

Risk factors of central venous lines-related thrombosis in children with acute lymphoblastic leukemia during induction therapy: a prospective study

Antithrombin III for critically ill patients

Antithrombin III for critically ill patients

Contact Info

Product

Resources

About